Dan Levangie Appointed as CEO ahead of FDA Approval and US Launch
Framingham, MA (PRWEB) October 25, 2011
Dilon Devices, Inc. today announced that a major symposium was conducted at the German Forum for Operative Gynecology (FOG) meeting in Berlin. Attended by over 75 leaders in the field of breast cancer in Germany, the symposium focused on the breakthrough results being achieved by European surgeons using Dune’s MarginProbe device during breast conserving surgery procedures in patients with early stage breast cancers.
Symposium presenter Marc Thill, M.D., Ph.D, Head of Gynecological Cancer Center and Head of Breast Center, Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Luebeck commented “This symposium, entitled “MarginProbe, tomorrow’s standard today?” demonstrated the outstanding results seen by centers in routine use. As we saw with the results of the German study presented in June, centers are experiencing tremendous success with the device, significantly reducing the number of patients who need to return to the operating room for a second surgery to address positive margins. Results are immediate, and it fits well with the standard surgical routine. I believe the MarginProbe will be widely adopted by surgeons in Germany and soon in Europe in order to improve patient outcomes.”
Separately, Dilon announced a change in senior management with the resignation of CEO, Bill Densel, who has left Dune to pursue other interests after leading the company during its pivotal FDA trial and PMA submission, and initial launch in Germany. The Board of Directors of Dune has appointed Daniel J. Levangie, as Chief Executive Officer, effective immediately. Mr. Levangie, a member of the Board of Directors of Dune since 2005, will continue as a director, and comes to this position after having spent 17 years at Cytyc Corporation in a variety of senior management positions, most recently serving as President of Cytyc’s Surgical Products Division. “During his tenure with Cytyc Corporation, Mr. Levangie led Cytyc’s emergence as an innovative medical device company focused on improving the surgical care of patients with early stage breast cancer. We believe his track record of success and his passion for this area of medical technology is an ideal combination to lead Dune through the completion of its US regulatory approval process and successful commercialization in the US and abroad. We are extremely excited to have Dan at the helm” said Dune’s Chairman, Amos Goren.
“We are thankful to Bill Densel for his substantial contribution to the growth of Dilon and wish him well in his future pursuits. I am very excited to continue my involvement with Dilon and to lead the team through our next series of opportunities including market penetration of western European markets and market introduction in the U.S. following FDA approval”, said Mr. Levangie.
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device in the U.S.
Dilon Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit http://dilon.com.
Dilon Devices, Inc.